Influenza Vaccine Workgroup

Matthew Bobo, MPH
Immunization Program Manager
DHSS/DPH/SOE
August 19, 2020
Agenda

Review the following:

• Stakeholder Group/Workgroup
• Influenza Surveillance and Vaccine Coverage
• 2020-2021 Influenza Vaccine
• Influenza Promotion Campaign
Please enter the code

23456

Submit

The code is found on the screen in front of you
Polling Question #1

Hand on heart, are you wearing PJs right now?

A. Business on top, PJs on bottom
B. I literally took them off a minute ago
C. 100% Yes
D. Never!
Polling Question #2

Where are you calling from?
Polling Question #3

What best describes your profession?

A. Medical Doctor
B. Nurse
C. Pharmacist
D. Public Health Nurse
E. Public Health Professional
F. Other
Polling Question #4

How are you feeling about the upcoming flu season?
Stakeholder Group/Workgroups
Improving Immunization Coverage
Stakeholder Group

• Goal 1: Increase influenza vaccine coverage among all Alaskans
  • Workgroup #1: Influenza Vaccine

• Goal 2: Promote influenza vaccine coverage among high risk and disparate populations

• Goal 3: Catch-up on childhood and adolescent vaccines

• Goal 4: Prepare for COVID-19 vaccine distribution
Influenza Surveillance and Vaccine Coverage
Surveillance: Flu Snapshot (cont.)

[Graphs showing flu activity in different regions: Northern, Mat-Su, Gulf Coast, Anchorage, Interior, Southwest, Southeast]
Surveillance: AK State Virology Laboratory (ASVL) Weekly Report

2017-2020 Influenza Season in Alaska - All Regions

- Influenza B (Yamagata)
- Influenza B (Victoria)
- Influenza A/H1 2009pdm
- Influenza A/H3

# Positive Specimens

Collection Date
To Sign-up for Surveillance Reports

Surveillance Data

Flu seasons are unpredictable and can range from mild to severe. Alaska typically has sporadic flu activity year round, some of it related to our robust tourism season, with peak activity occurring as early as November or as late as March.

› **Alaska Weekly Flu Snapshot Report**: a summary of a variety of different reports of influenza-related illness. From October through May, Snapshots are produced weekly to coincide with reporting during the national influenza season. During the summer months, Snapshots are generally produced monthly.

› **Alaska State Virology Weekly Report**: a summary of all specimens evaluated by the Lab in the previous week.

› **FluView**: the latest weekly U.S. flu surveillance summary from the CDC.

› **Flu Near You**: an online flu surveillance tool that allows the public to report their flu symptoms on a weekly basis, to help in tracking influenza activity.

• [http://dhss.alaska.gov/dph/Epi/id/Pages/influenza/fluinfo.aspx](http://dhss.alaska.gov/dph/Epi/id/Pages/influenza/fluinfo.aspx)
Flu Coverage: FluVaxView, 2010-11 – 2018-19

Influenza Vaccination Coverage by Season

Coverage(%) vs. Season

- 2010-11
- 2011-12
- 2012-13
- 2013-14
- 2014-15
- 2015-16
- 2016-17
- 2017-18
- 2018-19
2019-2020 Flu Coverage Rates

Source: VacTrAK
Polling Question #5

What do you think uptake for influenza vaccine will be like this year?

A. More people are eager to get vaccinated this year
B. About the same as last year
C. Fewer people want to get vaccinated this year
D. Unsure
2020-2021 Influenza Vaccine
State-supplied Influenza Vaccine Order Set Release

- *MMWR;* Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2020-2021 Influenza Season
  - Awaiting publication
- Epi Bulletin
- Expecting an August release
Polling Question #6

Do you have influenza vaccine already at your clinic?

A. Yes and we have started vaccinating
B. Yes, but we haven’t started vaccinating
C. No
D. Waiting on state-supplied influenza vaccine from the State
February 2020 Pre-book

• Every February Immunization Programs (64 awardees) pre-book influenza vaccine for the next influenza season (i.e., 2020-2021 influenza season)

Table. Pediatric Influenza Doses

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Brand</th>
<th>Description</th>
<th>Age</th>
<th>VFC Doses</th>
<th>317 Doses</th>
<th>AVAP Doses</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>FluMist-Quad</td>
<td>0.2mL single dose sprayer</td>
<td>2-49 years</td>
<td>3,500</td>
<td>40</td>
<td>2,250</td>
<td>5,790</td>
</tr>
<tr>
<td>GSK</td>
<td>Fluarix-Quad</td>
<td>0.5mL single dose syringe</td>
<td>6 months+</td>
<td>37,460</td>
<td>100</td>
<td>24,350</td>
<td>61,910</td>
</tr>
<tr>
<td>Sanofi</td>
<td>Fluzone-Quad</td>
<td>5mL multi-dose syringe</td>
<td>6 months+</td>
<td>7,650</td>
<td>50</td>
<td>4,900</td>
<td>12,600</td>
</tr>
<tr>
<td>Seqirus</td>
<td>Flucelvax-Quad</td>
<td>0.5mL single dose syringe</td>
<td>4 years+</td>
<td>940</td>
<td>10</td>
<td>550</td>
<td>1,500</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td></td>
<td></td>
<td>49,550</td>
<td>200</td>
<td>32,050</td>
<td>81,800</td>
</tr>
</tbody>
</table>
### Table. Adult Influenza Doses

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Brand</th>
<th>Description</th>
<th>Age</th>
<th>317 Doses</th>
<th>AVAP Doses</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>FluMist-Quad</td>
<td>0.2mL single dose sprayer</td>
<td>2-49 years</td>
<td>20</td>
<td>730</td>
<td>750</td>
</tr>
<tr>
<td>GSK</td>
<td>Fluarix-Quad</td>
<td>0.5mL single dose syringe</td>
<td>6 months+</td>
<td>1,480</td>
<td>33,840</td>
<td>35,320</td>
</tr>
<tr>
<td>Sanofi</td>
<td>Fluzone-Quad</td>
<td>5mL multi-dose syringe</td>
<td>6 months+</td>
<td>180</td>
<td>11,700</td>
<td>11,880</td>
</tr>
<tr>
<td>Sanofi</td>
<td>Fluzone-Quad HD</td>
<td>0.7mL prefilled syringe</td>
<td>65+ years</td>
<td>0</td>
<td>3,500</td>
<td>3,500</td>
</tr>
<tr>
<td>Seqirus</td>
<td>Flucelvax-Quad</td>
<td>0.5mL single dose syringe</td>
<td>4 years+</td>
<td>20</td>
<td>480</td>
<td>500</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>1,700</strong></td>
<td><strong>50,250</strong></td>
<td><strong>51,950</strong></td>
</tr>
</tbody>
</table>

TOTAL Pediatric + Adult = 133,750 influenza vaccine doses
May 2020 CDC Allocates Additional VFC Doses

Table. Additional VFC Doses

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Brand</th>
<th>Description</th>
<th>Age</th>
<th>VFC Doses</th>
<th>VFC + Doses</th>
<th>317 Doses</th>
<th>AVAP Doses</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>FluMist-Quad</td>
<td>0.2mL single dose sprayer</td>
<td>2-49 years</td>
<td>3,500</td>
<td>1,800</td>
<td>40</td>
<td>2,250</td>
<td>7,590</td>
</tr>
<tr>
<td>GSK</td>
<td>Fluarix-Quad</td>
<td>0.5mL single dose syringe</td>
<td>6 months+</td>
<td>37,460</td>
<td>100</td>
<td>24,350</td>
<td>61,910</td>
<td></td>
</tr>
<tr>
<td>Sanofi</td>
<td>Fluzone-Quad</td>
<td>5mL multi-dose syringe</td>
<td>6 months+</td>
<td>7,650</td>
<td>2,100</td>
<td>50</td>
<td>4,900</td>
<td>14,700</td>
</tr>
<tr>
<td>Seqirus</td>
<td>Flucelvax-Quad</td>
<td>0.5mL single dose syringe</td>
<td>4 years+</td>
<td>940</td>
<td>1,150</td>
<td>10</td>
<td>550</td>
<td>2,650</td>
</tr>
<tr>
<td>Sanofi</td>
<td>Fluzone-Quad</td>
<td>0.5mL pre-filled syringe</td>
<td>6 months+</td>
<td>510</td>
<td></td>
<td></td>
<td></td>
<td>510</td>
</tr>
<tr>
<td>Seqirus</td>
<td>Afluria-Quad</td>
<td>0.25mL pre-filled syringe</td>
<td>6-35 months</td>
<td>1,150</td>
<td></td>
<td></td>
<td></td>
<td>1,150</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>6,710</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>88,510</strong></td>
</tr>
</tbody>
</table>
60% of U.S. adults plan to get seasonal flu vaccine: Reuters/Ipsos poll

May 2020 Vaccine Population Coverage

<table>
<thead>
<tr>
<th></th>
<th>Pediatric Population (0 through 18 years old)</th>
<th>Adult Population (19+ years old)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Population (source: DLWD)</td>
<td>193,468</td>
<td>537,539</td>
</tr>
<tr>
<td>Doses as of May 2020</td>
<td>88,510</td>
<td>51,950</td>
</tr>
<tr>
<td>% of Population</td>
<td>46%</td>
<td>10%</td>
</tr>
</tbody>
</table>

Number of doses needed to get to 45% of the TOTAL population = 189,943 ($3.9M)
June 2020 Additional State Influenza Vaccine Doses

**Table.** Additional Influenza Vaccine Doses purchased by the State

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Brand</th>
<th>Description</th>
<th>Age</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>FluMist-Quad</td>
<td>0.2mL single dose sprayer</td>
<td>2-49 years</td>
<td>77,000</td>
</tr>
<tr>
<td>Seqirus</td>
<td>Flucelvax-Quad</td>
<td>0.5mL single dose syringe</td>
<td>4 years+</td>
<td>100,280</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>177,280</strong></td>
</tr>
</tbody>
</table>
July 2020 CDC conducted a Supplemental Adult Pre-Book

**Table.** Additional Adult Influenza Vaccine Doses purchased by CDC using 317 Funds

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Brand</th>
<th>Description</th>
<th>Age</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>FluMist-Quad</td>
<td>0.2mL single dose sprayer</td>
<td>2-49 years</td>
<td>12,220</td>
</tr>
<tr>
<td>GSK</td>
<td>Fluarix-Quad</td>
<td>0.5mL single dose syringe</td>
<td>6 months+</td>
<td>9,410</td>
</tr>
<tr>
<td>GSK</td>
<td>FluLaval-Quad</td>
<td>0.5mL single dose syringe</td>
<td>6 months+</td>
<td>9,410</td>
</tr>
<tr>
<td>Sanofi</td>
<td>Fluzone-Quad</td>
<td>5mL multi-dose syringe</td>
<td>6 months+</td>
<td>5,750</td>
</tr>
<tr>
<td>Sanofi</td>
<td>Fluzone-Quad</td>
<td>0.5mL single dose syringe</td>
<td>6 months+</td>
<td>19,400</td>
</tr>
<tr>
<td>Seqirus</td>
<td>Flucelvax-Quad</td>
<td>0.5mL single dose syringe</td>
<td>4 years+</td>
<td>15,890</td>
</tr>
<tr>
<td>Seqirus</td>
<td>Flucelvax-Quad</td>
<td>5mL multi-dose syringe</td>
<td>4 years+</td>
<td>9,410</td>
</tr>
<tr>
<td>Seqirus</td>
<td>Afluria-Quad</td>
<td>0.5mL single dose syringe</td>
<td>6 months+</td>
<td>6,480</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td>88,000</td>
</tr>
</tbody>
</table>
August 2020 Vaccine Population Coverage

<table>
<thead>
<tr>
<th>Total Population (source: DLWD)</th>
<th>Total Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doses as of August 2020</td>
<td>405,740</td>
</tr>
<tr>
<td>% of Population</td>
<td>55%</td>
</tr>
</tbody>
</table>
### Public vs. Private Market

Table. Doses administered during the 2019-2020 Influenza Season

<table>
<thead>
<tr>
<th></th>
<th>Number of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publicly Supplied</td>
<td>102,289</td>
</tr>
<tr>
<td>Privately Supplied</td>
<td>88,720</td>
</tr>
<tr>
<td>TOTAL</td>
<td>191,009</td>
</tr>
</tbody>
</table>

Source: VacTrAK
# Potential Vaccine Population Coverage with Private Market

<table>
<thead>
<tr>
<th>Total Population (source: DLWD)</th>
<th>731,007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doses as of August 2020</td>
<td>494,460</td>
</tr>
<tr>
<td>% of Population</td>
<td>67%</td>
</tr>
</tbody>
</table>
2020-2021 Influenza Season Vaccine Eligibility

• Due to the COVID-19 pandemic, the Alaska Immunization Program is waiving eligibility requirements for adults

  The following payers are not participating in AVAP:
  • Medicaid
  • Medicare
  • Insurance that does not cover vaccines
  • AlaskaCare Retirees Plan
  • Veterans Affairs (VA)

• Mark patient as “Ineligible”

• Eligibility MUST still be tracked (dose-level accountability)
Influenza Promotion Campaign
Polling Question #7

Do you have an influenza vaccine promotion campaign?

A. Yes
B. No
C. Use CDC’s promotion materials
D. Use State-developed promotion materials
E. Other
Draft
Influenza Material

DO YOUR PART TO KEEP THESE BEDS AVAILABLE.

GET YOUR FLU SHOT!

With limited health care capacity in Alaska, it's more important than ever this year for Alaskans to get a flu shot. We don't want our health care facilities dealing with high flu numbers and COVID at the same time. Make sure our health care resources are there for those who need it most.
Draft Influenza PSA

- https://vimeo.com/447222904/e399e1b873
Homework

1. Does your organization plan to conduct an influenza vaccine promotion campaign during the 2020-2021 influenza season? If so, can your organization share specifics of the campaign?

2. Would your organization be willing to partner with the Alaska Immunization Program on an influenza vaccine promotion campaign?

3. How much influenza vaccine stock does your organization plan to have for the 2020-2021 influenza season?

4. Would organizations be willing to touch base throughout the 2020-2021 influenza season to monitor overall influenza vaccine stock?

5. What else would you like to get out of this WG?

EMAIL: immune@alaska.gov
Polling Question #8

Will you get vaccinated this year?

A. Absolutely!
B. Heck, yes!
C. Of course!
D. I already did!